MedThink Inc., a Fingerpaint Group company
MedThink Inc., a Fingerpaint Group company
18 Division Street, Suite 212, Saratoga Springs, NY 12866
Quick facts
Accounts
- Account wins: 23
- Active business clients: 57
Finalist | MedComms Agency of the Year
Top left: Educational brochure for patients on how a rare disease is inherited.
Top right: Infographic for HCPs on infection risk in patients with multiple myeloma.
Lower left: Educational brochure on the connection between cardiovascular comorbidities and the CV risks of CML treatment.
Lower right: Peer-to-peer presentation for diagnosing Demodex blepharitis.
Brands by 2023 sales
- Brand-product accounts held: 137
Services mix
- Medical education: 27%
- Publications: 25%
- Medical affairs: 23%
- HCP: 12%
- Digital: 8%
- DTP: 5%
Finalist
- MedComms Agency of the Year
“In a rapidly changing world, MedThink, a Fingerpaint Group company, is leading the way in transforming medical communications,” agency leaders proclaim. “With a focus on digital transformation, generative AI, medical education, and collaboration between medical affairs and commercial teams, MedThink is revolutionizing how medical information is disseminated and communicated.”
“Our divisions, MedThink SciCom and MedThink Communications, each showed another year of double-digit growth as we led scientific exchange and shaped audience beliefs, closing the gap between scientific knowledge and clinical practice,” says Scott Goudy, president. “Through our focus on innovation, we help our clients provide enhanced value to physicians and patients navigating complex diseases. Our mission is to translate scientific knowledge into actionable insights that positively impact patient outcomes.”
Agency executives say at MedThink, “we understand the importance of accurate and timely information in the evolving healthcare landscape. We prioritize developing innovative and science-driven content that educates, inspires, and engages. By bridging the gap between preparing a product for the market and preparing the market for the product, we enable a comprehensive strategy that maximizes the reach and impact of our clients’ science and brands.”
Recent accomplishments
MedThink experienced “significant” growth, leaders say, adding 23 new clients and 137 new products across its divisions, MedThink SciCom and MedThink Communications. “The growth we experienced was divided equally between medical affairs and commercial clients,” Goudy says.
According to agency leaders, MedThink Communications saw increased medical education activities using behavioral insights and models to shape HCP beliefs. At the same time, opinion leader steering committee recommendations, including whitepapers and symposia, supplemented these activities. The division also deepened its expertise in ophthalmology with a robust peer-to-peer education program to support the launch of Xdemvy, the first FDA-
approved treatment for Demodex blepharitis. MedThink SciCom expanded its omnichannel and social media programs to amplify and elevate clinical content for several well-known pharmaceutical companies, launching groundbreaking initiatives such as the first-ever medical affairs-owned X handle and YouTube channel.
“These initiatives underscore our dedication to advancing medical discourse and education across digital platforms to enrich understanding and elevate care,” says Leslie Rotz, VP of digital strategy.
MedThink also formed what executives call “a novel, cross-divisional service offering clients integrated clinical trial recruitment support in an increasingly crowded and complex environment, including guidance for reaching diverse populations.” This venture allows the agency to offer clients a full spectrum of clinical trial services, including outreach with diverse populations through sister company Fingerpaint Multicultural.”
MedThink SciCom continued its thought leadership activities through webinars, articles, and conference presentations, reaching professionals across various industry domains.
Leaders say MedThink Communications explored generative AI’s potential, using it to develop creative concepts for clients and in new business opportunities.
Structure and services
As collaboration between medical affairs and commercial teams within pharma has increased, so has collaboration between MedThink SciCom and MedThink Communications. “While medical affairs has traditionally operated separately from commercial teams, more and more pharma companies recognize the value of enhanced collaboration,” according to Todd Parker, senior VP, managing director of MedThink SciCom. “This collaboration ensures that emerging scientific data and clinical insights are effectively integrated throughout all communication plans.”
According to John Kane, senior VP, managing director, MedThink Communications, the units’ unique structure and collaborative approach offer solutions to ensure that clinical insights generated by the medical affairs team are effectively integrated into the commercial strategy, helping pharma bridge the gap into the commercial environment.
“By combining our expertise in both medical affairs and commercial communications, we provide clients with the benefits of collaboration and synergy,” agency leaders state. “As pressure increases on pharmaceutical companies to get content into the market quickly, we can build on the institutional knowledge gained and deliver scientifically focused content to accelerate product adoption.”
In 2024, MedThink will continue strengthening the partnership between MedThink teams to provide clients with an integrated offering for exchanging market intelligence, identifying stakeholder insights, and enhancing customer engagement to close the gap between scientific knowledge and clinical practice, executives state.
Future plans
As the role of medical affairs continues to evolve, closer collaboration between MedThink SciCom and MedThink Communications presents opportunities to deliver enhanced value through strategic alignment and seamless communication, according to agency leaders. Additionally, integrating generative AI will enable the agency to identify novel solutions to clients’ challenges. “MedThink is perfectly positioned to take advantage of this evolving dynamic so that we can continue to close the gap between scientific knowledge and clinical practice.”
Philanthropy/citizenship
Giving back is woven into the DNA at MedThink and the Fingerpaint Group,” agency leaders say. “As an organization, we can boast of working with more than 100 nonprofits annually and are proud to say that 100 percent of our employees participate in philanthropy activities. Giving back is an integral part of who we are.”
Recently, MedThink developed the visual identity for Hope Connection International (HCI) and will execute several marketing initiatives for them in 2024. HCI is a recovery and prevention center that connects survivors of abuse and addiction with support groups, tailored solutions, and long-term housing.
